PT  - JOURNAL ARTICLE
AU  - Daniel J Wallace
AU  - Karin Tse
AU  - Leslie Hanrahan
AU  - Rupert Davies
AU  - Michelle A Petri
TI  - Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America
AID  - 10.1136/lupus-2019-000317
DP  - 2019 Mar 01
TA  - Lupus Science & Medicine
PG  - e000317
VI  - 6
IP  - 1
4099  - http://lupus.bmj.com/content/6/1/e000317.short
4100  - http://lupus.bmj.com/content/6/1/e000317.full
SO  - Lupus Sci & Med2019 Mar 01; 6
AB  - The majority of patients with SLE in the USA have been prescribed hydroxychloroquine (HCQ). Given more recent guidelines, the availability of only one strength (200 mg tablets) may limit the flexibility and ability to accurately dose patients with lupus. The Lupus Foundation of America undertook a survey to assess the current landscape of HCQ tolerability and adherence.